• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌转移的代谢机制

The Metabolic Mechanisms of Breast Cancer Metastasis.

作者信息

Wang Lingling, Zhang Shizhen, Wang Xiaochen

机构信息

Department of Breast Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.

Department of Surgical Oncology and Cancer Institute, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Front Oncol. 2021 Jan 7;10:602416. doi: 10.3389/fonc.2020.602416. eCollection 2020.

DOI:10.3389/fonc.2020.602416
PMID:33489906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7817624/
Abstract

Breast cancer is one of the most common malignancy among women worldwide. Metastasis is mainly responsible for treatment failure and is the cause of most breast cancer deaths. The role of metabolism in the progression and metastasis of breast cancer is gradually being emphasized. However, the regulatory mechanisms that conduce to cancer metastasis by metabolic reprogramming in breast cancer have not been expounded. Breast cancer cells exhibit different metabolic phenotypes depending on their molecular subtypes and metastatic sites. Both intrinsic factors, such as amplification, , and mutations, and extrinsic factors, such as hypoxia, oxidative stress, and acidosis, contribute to different metabolic reprogramming phenotypes in metastatic breast cancers. Understanding the metabolic mechanisms underlying breast cancer metastasis will provide important clues to develop novel therapeutic approaches for treatment of metastatic breast cancer.

摘要

乳腺癌是全球女性中最常见的恶性肿瘤之一。转移是导致治疗失败的主要原因,也是大多数乳腺癌死亡的原因。代谢在乳腺癌进展和转移中的作用正逐渐受到重视。然而,乳腺癌中通过代谢重编程导致癌症转移的调控机制尚未阐明。乳腺癌细胞根据其分子亚型和转移部位表现出不同的代谢表型。内在因素,如扩增、 、和突变,以及外在因素,如缺氧、氧化应激和酸中毒,都导致转移性乳腺癌中不同的代谢重编程表型。了解乳腺癌转移背后的代谢机制将为开发治疗转移性乳腺癌的新治疗方法提供重要线索。

相似文献

1
The Metabolic Mechanisms of Breast Cancer Metastasis.乳腺癌转移的代谢机制
Front Oncol. 2021 Jan 7;10:602416. doi: 10.3389/fonc.2020.602416. eCollection 2020.
2
The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications.乳腺癌的代谢格局及其治疗意义。
Mol Diagn Ther. 2023 May;27(3):349-369. doi: 10.1007/s40291-023-00645-2. Epub 2023 Mar 29.
3
Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications.乳腺癌中的代谢重编程及其治疗意义。
Cells. 2019 Jan 26;8(2):89. doi: 10.3390/cells8020089.
4
Metabolic Reprogramming Underlying Brain Metastasis of Breast Cancer.乳腺癌脑转移的代谢重编程
Front Mol Biosci. 2022 Jan 5;8:791927. doi: 10.3389/fmolb.2021.791927. eCollection 2021.
5
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.PDK1 依赖性代谢重编程决定乳腺癌的转移潜能。
Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10.
6
Metabolic Reprogramming in Triple-Negative Breast Cancer.三阴性乳腺癌中的代谢重编程
Front Oncol. 2020 Mar 31;10:428. doi: 10.3389/fonc.2020.00428. eCollection 2020.
7
Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.中国转移性乳腺癌患者癌症基因突变特征分析
Front Oncol. 2020 Jun 30;10:1023. doi: 10.3389/fonc.2020.01023. eCollection 2020.
8
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.未经治疗的仅发生骨转移和非骨部位首次转移的乳腺癌患者的体细胞突变、临床病理特征及生存情况
J Cancer. 2018 Sep 8;9(19):3640-3646. doi: 10.7150/jca.26825. eCollection 2018.
9
Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.通过Myc抑制TXNIP实现三阴性乳腺癌中的代谢重编程
Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5425-30. doi: 10.1073/pnas.1501555112. Epub 2015 Apr 13.
10
Metabolic reprogramming: the emerging concept and associated therapeutic strategies.代谢重编程:新兴概念及相关治疗策略
J Exp Clin Cancer Res. 2015 Oct 6;34:111. doi: 10.1186/s13046-015-0221-y.

引用本文的文献

1
The Antitumor Role of Incomptine A in a Breast Cancer Murine Model: Impairment of Hexokinase II Expression and Apoptosis Induction.Incomptine A在乳腺癌小鼠模型中的抗肿瘤作用:己糖激酶II表达的损害与凋亡诱导
Cells. 2025 Aug 2;14(15):1192. doi: 10.3390/cells14151192.
2
Rare Case of Metastatic Breast Cancer to the Sphenoid Sinus: Diagnosis and Treatment.蝶窦转移性乳腺癌罕见病例:诊断与治疗
Case Rep Oncol. 2025 Jul 8;18(1):1040-1049. doi: 10.1159/000546040. eCollection 2025 Jan-Dec.
3
Path-MGCN: a pathway activity-based multi-view graph convolutional network for determining spatial domains.

本文引用的文献

1
Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial.紫杉烷化疗联合或不联合吲哚莫德治疗转移性乳腺癌的随机临床试验
JAMA Oncol. 2021 Jan 1;7(1):61-69. doi: 10.1001/jamaoncol.2020.5572.
2
Hepatic lipids promote liver metastasis.肝内脂质促进肝转移。
JCI Insight. 2020 Sep 3;5(17):136215. doi: 10.1172/jci.insight.136215.
3
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer.靶向葡萄糖代谢以克服乳腺癌对抗癌化疗的耐药性
Path-MGCN:一种基于通路活性的多视图图卷积网络,用于确定空间域。
Brief Bioinform. 2025 Jul 2;26(4). doi: 10.1093/bib/bbaf365.
4
Hypoxanthine activates PI3K/AKT pathway and lipid metabolism, hallmarks in breast cancer metastasis.次黄嘌呤激活PI3K/AKT通路和脂质代谢,这是乳腺癌转移的特征。
Med Oncol. 2025 Jun 16;42(7):263. doi: 10.1007/s12032-025-02829-8.
5
Mechanisms of organotropism in breast cancer and predicting metastasis to distant organs using deep learning.乳腺癌的器官otropism机制及使用深度学习预测远处器官转移
Discov Oncol. 2025 Jun 11;16(1):1056. doi: 10.1007/s12672-025-02905-5.
6
Patient-derived organotypic tissue cultures as a platform to evaluate metabolic reprogramming in breast cancer patients.患者来源的器官型组织培养作为评估乳腺癌患者代谢重编程的平台。
J Biol Chem. 2025 May;301(5):108495. doi: 10.1016/j.jbc.2025.108495. Epub 2025 Apr 8.
7
Ketomimetic nutrients remodel the glycocalyx and trigger a metabolic defense in breast cancer cells.酮体模拟营养素重塑糖萼并触发乳腺癌细胞的代谢防御。
Cancer Metab. 2025 Apr 9;13(1):18. doi: 10.1186/s40170-025-00385-3.
8
CDK4/6 as a Therapeutic Target in HR+/HER2- Breast Cancer Cells-Current Treatment Status.细胞周期蛋白依赖性激酶4/6作为激素受体阳性/人表皮生长因子受体2阴性乳腺癌细胞的治疗靶点——当前治疗现状
Cancers (Basel). 2025 Mar 20;17(6):1039. doi: 10.3390/cancers17061039.
9
Usefulness of Indian Diabetes Risk Score in Predicting Treatment-Induced Hyperglycemia in Women Undergoing Adjuvant Chemotherapy for Breast Cancer.印度糖尿病风险评分在预测接受乳腺癌辅助化疗的女性治疗诱导的高血糖中的效用。
South Asian J Cancer. 2023 Oct 13;14(1):4-14. doi: 10.1055/s-0043-1775805. eCollection 2025 Jan.
10
Dual inhibitor of MDM2 and NFAT1 for experimental therapy of breast cancer: and anticancer activities and newly discovered effects on cancer metabolic pathways.用于乳腺癌实验性治疗的MDM2和NFAT1双重抑制剂:抗癌活性及对癌症代谢途径的新发现作用
Front Pharmacol. 2025 Feb 19;16:1531667. doi: 10.3389/fphar.2025.1531667. eCollection 2025.
Cancers (Basel). 2020 Aug 12;12(8):2252. doi: 10.3390/cancers12082252.
4
Metabolism of immune cells in cancer.癌症中的免疫细胞代谢。
Nat Rev Cancer. 2020 Sep;20(9):516-531. doi: 10.1038/s41568-020-0273-y. Epub 2020 Jul 6.
5
Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer.不同肿瘤 PIK3CA 突变与接受芳香化酶抑制剂治疗的激素受体阳性转移性乳腺癌患者中阿司匹林使用相关的临床结局的相关性。
BMC Cancer. 2020 Apr 23;20(1):347. doi: 10.1186/s12885-020-06810-8.
6
Metabolic reprogramming and cancer progression.代谢重编程与癌症进展。
Science. 2020 Apr 10;368(6487). doi: 10.1126/science.aaw5473.
7
Cancer-associated fibroblast heterogeneity in axillary lymph nodes drives metastases in breast cancer through complementary mechanisms.腋窝淋巴结中癌相关成纤维细胞的异质性通过互补机制促进乳腺癌转移。
Nat Commun. 2020 Jan 21;11(1):404. doi: 10.1038/s41467-019-14134-w.
8
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
9
Metabolic crosstalk in the breast cancer microenvironment.乳腺癌微环境中的代谢串扰。
Eur J Cancer. 2019 Nov;121:154-171. doi: 10.1016/j.ejca.2019.09.002. Epub 2019 Sep 30.
10
Potential Role of MSC/Cancer Cell Fusion and EMT for Breast Cancer Stem Cell Formation.间充质干细胞/癌细胞融合及上皮-间质转化在乳腺癌干细胞形成中的潜在作用
Cancers (Basel). 2019 Sep 25;11(10):1432. doi: 10.3390/cancers11101432.